- Low
- 49,200
- Average
- 110,888
- Median
- 99,514
- High
- 375,000
Alexion Pharmaceuticals Salary
83
50
48
Related Alexion Pharmaceuticals Salary
- CVS Salary
- Mayo Clinic Salary
- Cerner Salary
- Medtronic Salary
- Amgen Salary
- Datarich Management Systems Salary
- Polaris Software India (lab) Salary
- Iet Salary
- Marion County School District Salary
- Intelligrated Headquarters Salary
- Angie's List Salary
- Jasstek Salary
- Cohnreznick Salary
- Shalom Media Usa Salary
Calculate how much you could earn
It's FREE. Based on your input and our analysis. How we do it?
All fields are required for calculation accuracy.
- We will send you an email to access your personalized report.
- We won’t share your email address
Real Jobs Salary - Salary List- 8.5 million company & government reported salaries with date & location
- Salary calculator rank & calculate your salary
- 151 million W-2s pay scale statistics in U.S.
- Salary Map helps you navigate location based salary information
- State & City Salary provides wage data by metropolitan areas
- Company Salaries has salaries data from over 200,000 companies
Guyp Salary Alexion Pharmaceuticals Jobs
| See more Alexion Pharmaceuticals Jobs» | |
| Search All Jobs | |
Patents information
2181
All Patents
386
Grant Patents
1544
Patents Pending
700
Patents Families
More Recent
-
EP4306128A3SUBCUTANEOUS DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
-
EP4306128A2SUBCUTANEOUS DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
-
US20240026032A1Antibody Immune Cell Inhibitor Fusion Proteins
- View More »
Alexion Pharmaceutical... Information
- Alexion Pharmaceuticals Inc
- Industry: BioTech/Drugs
- City: Cheshire, CT
- Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune disorders. The Company has one marketed product, Soliris (eculizumab), which is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In June 2007, the European Commission (E.C.) approved the use of Soliris for patients with PNH in the European Union, which also serves as the basis for approval in Iceland and Norway. Alexion has focused its product development programs on anti-inflammatory therapeutics for diseases.(Source: 10-K)
